News

Evonik and Bioamber team up
Enlarge image

BusinessGermany

Evonik and Bioamber team up

25.07.2012 - Evonik Industries and BioAmber join forces on catalysts for sustainable chemicals made from bio-based succinic acid.

Under the terms of the agreement, Evonik and Bioamber will jointly develop and manufacture catalysts for making BDO (1,4- butanediol), THF (tetrahydrofurane) and GBL (gamma - butyrolactone) from bio-based succinic acid. BDO, THF and GBL are large volume industrial chemicals used in a wide range of applications including polymers, paints, adhesives and solvents. The global market for these products, currently made from petrochemicals, is $4bn.

The two companies are well known to each other. Back in 2010, they started a joint development programme for a new generation of BDO catalysts. "Through our collaboration with Evonik, we have secured the expertise and capabilities we need to rapidly bring competitive BDO and THF technology to market," said Jean-Francois Huc, BioAmber CEO. "We are fortunate to have a partner of Evonik’s calibre who can both optimise and manufacture our immediate catalyst needs and also develop with us a new generation of catalysts," Huc added. Bioamber operates the world’s only dedicated production plant for bio-succinic acid in Pomacle, France with a 350,000 litre commercial scale fermenter. The US-based company is pouring more money into building new plants around the globe. Together with Mitsui & Co., it has broken ground in Sarnia, Canada on a 17,000 metric ton bio-succinic acid plant that will be operational in late 2013, with plans to expand capacity to 34,000 metric tons of succinic acid, and a 23,000 metric tons BDO plant in late 2014.

In order to fuel 1st growth, Bioamber has completed its Series C round of financing with net proceeds of $30m. The financing was closed in two tranches; a first tranche of $20m on November last year with existing investors Naxos Capital, Sofinnova Partners, Mitsui & Co. Ltd. and the Cliffton Group. A second tranche of $10m followed this February with specialty chemicals company Lanxess. All of BioAmber’s Series B investors participated in the Series C financing.

http://www.european-biotechnology-news.com/news/news/2012-03/evonik-and-bioamber-team-up.html

FinancingFrance

21.10.2014 Yet another European company is looking for money on the US stock exchange – French DBV Technologies SA is all set up for its secondary listing on NASDAQ. The French biotech company hopes to rake in US$98m for its peanut allergy patches.

FinancingDenmark

18.10.2014 After raising US$220.5m (€172m) with its IPO, fast Forward Pharma’s lucky streak hits an obstacle on the road to success with shares falling 17% on its first day of trading.

M&AUKItaly

17.10.2014 Abandoned at the altar: Abbvie has dropped plans to acquire UK’s Shire following new US tax rules. This puts a stop to one of the biggest pharma mergers planned this year.

FinancingUKBelgium

15.10.2014 Bicycle Therapeutics wins €25m backing by major pharma venture capitalists for the development of a new class of oncology drugs.

FinancingGermanySwitzerlandNetherlands

13.10.2014 Biotechnology IPOs are back in fashion – German Probiodrug AG wants to raise €32m with its IPO, whilst Swiss Molecular Partners AG hopes the launch of its IPO will gain a revenue of €145m.

BusinessIreland

10.10.2014 Actavis has announced plans to merge with American pharma company Durata - a move that will strengthen their infectious diseases portfolio.

RegulationEU

07.10.2014 In an unprecedented move, the European Medicines Agency has approved a system allowing the future analysis of clinical trial data.

FinanceNetherlandsEU

06.10.2014 Another fund from the Netherlands has raised €92m in its first close and will invest the money in companies developing innovative therapeutics, medical devices and diagnostics.

FinanceNetherlandsUKSwitzerland

03.10.2014 Dutch venture capitalist LSP has achieved its monetary milestone by raising €80m for its fifth fund - with a goal of €150m.

PoliticsEULithuaniaPoland

02.10.2014 New EU commission chief Jean-Claude Juncker is on the defensive after members of Parliament and NGOs criticised his reorganisation of the health technology units.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • MEDIGENE3.85 EUR8.15%
  • EVOTEC2.87 EUR7.49%
  • 4SC0.84 EUR5.00%

FLOP

  • CYTOS0.15 CHF-6.25%
  • EPIGENOMICS3.42 EUR-0.87%
  • STRATEC BIOMEDICAL37.50 EUR-0.87%

TOP

  • BIOFRONTERA2.91 EUR29.9%
  • ADDEX3.44 CHF5.8%
  • HBM86.00 CHF3.7%

FLOP

  • PAION2.19 EUR-32.6%
  • CYTOS0.15 CHF-28.6%
  • 4SC0.84 EUR-26.3%

TOP

  • SANTHERA82.00 CHF2269.9%
  • CO.DON2.82 EUR209.9%
  • PAION2.19 EUR154.7%

FLOP

  • CYTOS0.15 CHF-96.2%
  • 4SC0.84 EUR-51.7%
  • THERAMETRICS0.07 CHF-46.2%

No liability assumed, Date: 21.10.2014